Johnson & Johnson said Monday it was in discussions with the U.S. Food and Drug Administration about rare cases of a neurological disorder, Guillain-BarreĢ syndrome, that have been reported following vaccination with the Janssen COVID-19 vaccine.Continue reading at Newsmax